Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-1: Vercirnon in Moderate to Severe Crohn's Disease
NCT00306215Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of vercirnon in Crohn's disease (4 arms), sponsored by Amgen. Primary endpoint: Percentage of subjects achieving a clinical response at Day 57. Started Mar 2006; status: completed.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00306215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306215.